FDA EMA clinical immunogenicity safety assessments first video
FDA EMA clinical immunogenicity safety assessments second video
Panel Discussion: Regulatory Issues in Gene Therapy Approval in EMA Region
FDA’s Efforts to Advance the Development and Approval of Cellular and Gene Therapies
Introduction to Advanced Therapy Medicinal Products (ATMPs) in the EU
Featured Fireside Chat: EMA Perspective
Webinar: The FDA and EMA’s Unwavering Request Submitting Phase Appropriate Genetic Data (Cergentis)
Panel Discussion on Gene Therapy Policy in Europe
LHON Awareness Day 2024 Webinar
EIC – EMA Info Day: Regulatory support for the development of innovative medicines and technologies
EMA & EATRIS present: Scientific Advice for Advanced Therapy Medicinal Products: What & When to Ask
Keynote Speaker: The EMA's Plan for Continuing Acceleration of the ATMP Sector
A-Gene: Regulatory Considerations
Featured Fireside Chat: Brexit's Effect on Cell and Gene Therapy Regulation
Cell and Gene Therapy: Advancing the Next Generation of Pharmaceuticals
Global Regulatory Environment for Gene Therapy Development, Dr. Keith Wonnacott (USA)
Commercial and Regulatory Success in Accelerated Gene Therapy Development
New Drug Approvals by FDA & EMA in 2021
A-Cell: Regulatory Considerations
What is FDA Breakthrough Therapy Designation? What is EMA PRIME Medicine Status?
